14. Department of Health and Human Services · Notable
Restrict pharmaceutical direct-to-consumer advertising
Printed page 460 14. Department of Health and Human Services
“The FDA or Congress should regulate where and how paid advertising is used by pharmaceutical companies more stringently, especially on media outlets.”
What has happened
- Partially done
The President directed HHS and FDA to tighten direct-to-consumer prescription drug advertising, and the FDA enforced the same day. The memorandum of 2025-09-09 tells the Secretary to increase the risk information such advertisements must carry and the Commissioner of Food and Drugs to enforce the Federal Food, Drug, and Cosmetic Act's advertising provisions; FDA's release of the same date says it is sending thousands of letters warning companies to remove misleading advertisements and approximately 100 cease-and-desist letters, and that it is initiating rulemaking to close the 1997 "adequate provision" loophole for broadcast advertisements. The Office of Prescription Drug Promotion's own index of its untitled letters bears that out: 52 letters dated 2025-09-09 to AbbVie, AstraZeneca, Novartis, Pfizer, Bristol Myers Squibb, Takeda, UCB, Boehringer Ingelheim and others, and 82 in all from that date to 2026-08-21, against three in the seven months before the memorandum and — by FDA's own count — one warning letter in 2023 and none in 2024. `partial`, not `done`: stricter enforcement of the existing fair-balance rules is a piece of what the Quote asks for, delivered and dated; the regulation-tightening half has not moved — FDA has published no proposed or final rule on prescription drug advertising in the window, and the 2026 Unified Agenda still lists the subject as a planned action. Congress has not acted either; the Responsibility in Drug Advertising Act (S. 483, H.R. 1117) and the No Handouts for Drug Advertisements Act (H.R. 3010, S. 1785) are all in committee.
- Presidential Memorandum: Addressing Misleading Direct-To-Consumer Prescription Drug Advertisements
- FDA news release, FDA Launches Crackdown on Deceptive Drug Advertising — thousands of warning letters and about 100 cease-and-desist letters sent; rulemaking on the adequate-provision loophole initiated
- FDA, Office of Prescription Drug Promotion untitled letters index — 52 letters dated 2025-09-09 and 82 from that date to 2026-08-21, as read 2026-09-06
Research log
What was searched, and what didn’t count as evidence
Research notes
- Read 2026-09-06. www.fda.gov can be read; the earlier refusals came from a different kind of request. OPDP’s untitled-letters index (fda.gov/drugs/warning-letters-and-notice-violation-letters-pharmaceutical-companies/untitled-letters) lists 117 letters back to 2017; parsed by date: 3 between 2025-01-20 and 2025-09-08 (Edenbridge 2025-02-03, Taiho 2025-03-21, Mayne 2025-04-28), 52 dated 2025-09-09, 82 from 2025-09-09 to 2026-08-21, the latest to Alar Pharmaceuticals. The general warning-letters database (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) returns 157 entries for “Prescription Drug Promotion”, the most recent a 2026-06-08 set of telehealth “False & Misleading Claims/Misbranded” letters from CDER; not counted above because the database search is free-text over excerpts.
- The rulemaking limb: still nothing. The 2025-09-09 release says FDA “is initiating rulemaking”; no NPRM has appeared, which is what keeps the item at partial.
- Full-text Federal Register searches for “prescription drug advertisement” (0 documents) and for “advertising” restricted to FDA (20 documents, all tobacco, biosimilar labeling or information collections) confirm no rulemaking yet.
- Action
- restrict
- Object
- pharmaceutical direct-to-consumer advertising
- ID
- 1242